PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
10. Februar 2021 02:31 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released...
PCI Biotech to present at RNA Therapeutics Virtual Conference
22. Januar 2021 06:04 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Successful Phase I fimaVacc vaccination proof of concept study to be published in Frontiers in Immunology
23. November 2020 02:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 23 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the results from the successful Phase I proof of concept study for the...
PCI Biotech: European patent for treatment of bile duct cancer with the fimaChem technology
16. November 2020 02:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 16 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the European Patent Office (EPO) has informed the company that a new...
PCI Biotech third quarter 2020 results
11. November 2020 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 11 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2020 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to third quarter 2020 results presentation
04. November 2020 03:15 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 4 November 2020 - PCI Biotech’s (OSE: PCIB) third quarter 2020 interim report will be released on 11 November 2020 at 07.00 CET. The interim report and presentation will be made...
PCI Biotech: First patient enrolled in Asia in the fimaCHEM pivotal RELEASE study
26. Oktober 2020 07:48 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 October 2020 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Preclinical research collaboration with big pharma ended
21. Oktober 2020 02:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 21 October 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today informed that AstraZeneca has elected not to enter into a definitive agreement for the...
PCI Biotech: Employee share option scheme
06. Oktober 2020 09:02 ET
|
PCI Biotech Holding ASA
Oslo, 06 October 2020 In accordance with the authorisation granted by the Annual General Meeting 27 May 2020, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 540,000 share...
PCI Biotech: Capital increase registered and listing of new shares
08. September 2020 06:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 8 September 2020. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 60,500 new shares following...